Egis in the World

Our products reach 100 countries

Click here to learn more

Pharma Company

Our activities incorporate all areas of the pharmaceutical value chain

Click here to learn more

Research & Development

Innovation is one of the pillars of our strategy. We devoted EUR 48 million to research and development in the 2022/2023 business year.

Click here to learn more
Own subsidiaries / Representative offices
Sales through Partners
Egis World

This was the year we commemorated the 110th anniversary of the foundation of our company

Continuous modernisations and investment, launch of a new line of business, tree planting, exhibitions, and a short story contest. In 2023 Egis

More
Egis World

Egis' medicines won the Innovation Grand Prize

Two of Egis’ fixed-dose combination drugs have won the Innovation Grand Prize. The awarded Egis medicines feature significant innovations as they reduce the risk of cardiovascular events related to atherosclerosis due to the combined

More
Egis World

Celebrating our company’s 110th anniversary

The predecessor of Egis Pharmaceuticals PLC, Dr Wander Pharmaceuticals and Nutriments Ltd. was registered on 19 February 1913.

More
More articles

Egis in the World

Egis’ products reach 100 countries around the world.

Egis ’products reach countries. Our portfolio consists of 653 products.  Our main focus lies on treating diseases of the cardiovascular and central nervous systems.

Learn more

A place to work

Join us!

Healthcare Professionals

and prescription drugs

Professional content for our medical and pharmaceutical visitors. These contents are available with password protection - please contact our representative or require your own account at the Contact menu.

Learn more
Therapeutic areas
Therapeutic areas
Allergology
Cardiovascular system
Central nervous system
Gastroenterology
Women´s health
WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox